Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

I-Mab Approved to Start US Trials of Immunotherapy, its Third US Approval This Month

publication date: Jan 28, 2019

I-Mab Biopharma of Suzhou nabbed its third US IND approval to start clinical trials of an innovative drug this month. The two-year-old company was OK'd to begin tests of its fully human anti-CD47 mAb (TJC4), which it discovered and developed itself. Previously, I-Mab was approved to begin trials of a CD73 antibody in patients with solid tumors and a humanized immunoglobulin for autoimmune and inflammatory diseases. I-Mab plans to start Phase I/Ib clinical trials of its newest approved candidate, TJC4, in patients with solid tumors and lymphoma as a monotherapy and in combination therapies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital